The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments by Anckaert, Ellen et al.
ORIGINAL ARTICLE Reproductive endocrinology
The value of anti-Mu ¨llerian hormone
measurement in the long GnRH
agonist protocol: association with
ovarian response and gonadotrophin-
dose adjustments
Ellen Anckaert1, Johan Smitz1,*, Johan Schiettecatte1, Bjarke M Klein2,
and Joan-Carles Arce2
1UZ Brussel, Laboratory of Clinical Chemistry and Radio-immunology, Vrije Universiteit Brussel (VUB), Brussel, Belgium
2Ferring
Pharmaceuticals A/S, Global Clinical & Non-Clinical R&D, Copenhagen, Denmark
*Correspondence address. Fax: +32-2-4775060; E-mail: johan.smitz@uzbrussel.be
Submitted on October 7, 2011; resubmitted on February 21, 2012; accepted on March 1, 2012
background: This study evaluated the predictive value of serum and follicular ﬂuid (FF) concentrations of anti-Mu ¨llerian hormone
(AMH) with respect to treatment outcome variables in an IVF cycle.
methods: A retrospective analysis was performed with data from 731 normogonadotrophic women undergoing controlled ovarian
stimulation after stimulation with highly puriﬁed menotrophin (HP-hMG) or rFSH following a long GnRH agonist protocol.
results: In both treatment groups, the serum AMH concentration at the start of the stimulation was signiﬁcantly (P , 0.001) positively
correlated with the serum levels of estradiol (HP-hMG: r ¼ 0.45; rFSH: r ¼ 0.55), androstenedione (HP-hMG: r ¼ 0.50; rFSH: 0.49) and total
testosterone (HP-hMG: r ¼ 0.40; rFSH: r ¼ 0.36) at the end of the stimulation as well as the number of oocytes retrieved (HP-hMG: r ¼
0.48; rFSH: r ¼ 0.62), the AMH concentration in FF (HP-hMG: r ¼ 0.55; rFSH: 0.61) and the serum progesterone concentration (HP-hMG:
r ¼ 0.39; rFSH: r ¼ 0.50) at oocyte retrieval. For both treatments, serum AMH at the start of the stimulation was a good predictor of the
need to increase or decrease the gonadotrophin dose on stimulation day 6 and of ovarian response below (,7 oocytes) or above (.15
oocytes) the target. No signiﬁcant relationships were observed between serum AMH and embryo quality or ongoing pregnancy.
conclusion: The serum AMH concentration at the start of the stimulation in IVF patients down-regulated with GnRH agonist in the
long protocol revealed a positive relationship with ovarian response to gonadotrophins in terms of oocytes retrieved and accompanying
endocrine response. AMH is a good predictor of the need for gonadotrophin-dose adjustment on stimulation day 6 for patients with a
ﬁxed starting dose, but a poor predictor of embryo quality and pregnancy chances in individual patients.
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Introduction
Anti-Mu ¨llerian hormone (AMH) is a glycoprotein belonging to the
transforming growth factor-b superfamily (Cate et al, 1986). In
women, AMH is produced solely by the ovarian granulosa cells. Its ex-
pression is low in primary follicles but increases to maximal levels in
pre-antral and small antral follicles (up to 6–7 mm in diameter).
AMH expression gradually declines as follicles increase further in
size and ultimately becomes undetectable at a stage where
FSH-dependent follicular growth has been initiated (Weenen et al.,
2004). AMH is not expressed in atretic follicles.
AMH plays a role in the control of follicle growth via paracrine
and autocrine effects. Both in vitro and in vivo studies have shown
that AMH inhibits the recruitment of resting follicles from the prim-
ordial follicle pool (Durlinger et al., 1999; Carlsson et al., 2006) and
AMH decreases the sensitivity of small antral follicles to FSH (Dur-
linger et al., 2001). The serum level of AMH is a marker of the
ovarian reserve; the number of antral follicles has been shown to
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of FSH (Fanchin et al., 2003a). Moreover, AMH appears to be the
earliest endocrine marker of ovarian aging (de Vet et al., 2002).
The serum AMH level shows only minimal ﬂuctuations during the
menstrual cycle (La Marca et al., 2006), reﬂecting the continuous non-
cyclic growth of pre-antral and small antral follicles (independent of
FSH). Furthermore, the serum level of AMH displays a high inter-cycle
reproducibility. Consequently, only a single blood sample is sufﬁcient
for a reliable assessment of the ovarian reserve, compared with
three measurements for FSH (Fanchin et al., 2005). Serum AMH has
also been shown to demonstrate less intra- and inter-cycle variation
than the antral follicle count (AFC), suggesting that the AMH constitu-
tes a more reliable and robust marker of ovarian reserve than the
actual AFC assessment (van Disseldorp et al., 2010). An association
between basal AMH and ovarian response to gonadotrophin was
ﬁrst reported by Seifer et al. (2002). Since then, a number of studies
have claimed AMH to be superior to the age of the patient and
measurements of FSH, estradiol and inhibin B on cycle day 2–3 in
predicting oocyte yield in IVF (La Marca et al., 2010).
A few studies have assessed the effect of controlled ovarian
stimulation (COS) on AMH secretion by the ovary. Unlike normal
menstrual cycles where the serum AMH concentration does not
change signiﬁcantly, serum AMH levels have been demonstrated to de-
creasegraduallyduringthefollicularphaseinbothpituitary-desensitized
GnRH agonist cycles (Fanchin et al., 2003b; La Marca et al., 2004) and
GnRH antagonist cycles (Lee et al., 2010). The steady decrease in
AMH levels during the follicular phase of the COS cycle has been
suggested to reﬂect the change in follicle distribution, i.e. reduced
numbers of small antral follicles and increased numbers of enlarged
follicles, in response to the FSH stimulation (Fanchin et al., 2003b). In
addition,FSHandestradiolhavebeenreportedtosuppressAMHsecre-
tion(Baarends et al., 1995; Pellattet al., 2007), which maycontribute to
the decrease in AMH concentrations during COS.
Serum level of AMH has been demonstrated to be a good
prognostic marker for poor ovarian response, cycle cancellation and
hyper-response to COS. Importantly, a recent large prospective
(but non-randomized) study suggested that an AMH-based approach
to individualize treatment strategies for COS may result in a
reduced risk of hyper-response with maintained pregnancy rates
(Nelson et al., 2009). It should be noted that most of the studies in-
vestigating the prognostic value of AMH in predicting ovarian response
and/or outcome in ART have only included rFSH-treated cycles. To
date, no studies have compared the usefulness of AMH measurements
when different gonadotrophin preparations are used for stimulation.
Although it is recognized that embryo morphology grading is only a
weak predictor of clinical outcome, one study has found a positive
relationship between serum AMH after stimulation and embryo
morphology (Silberstein et al., 2006), while others have demonstrated
no correlation between basal serum AMH and embryo quality (Ebner
et al., 2006; Smeenk et al., 2007; Lie Fong et al., 2008). Likewise, some
studies have found serum AMH to be a predictor of pregnancy
(Hazout et al., 2004; Eldar-Geva et al., 2005; Lekamge et al., 2007;
Elgindy et al., 2008), while other studies (van Rooij et al., 2002;
Pen ˜arrubia et al., 2005; Fic ¸icioglu et al., 2006; Smeenk et al.,
2007; Kwee et al., 2008) and recent meta-analyses (Broer et al.,
2009, 2010) could only attribute a poor predictive value to serum
AMH for pregnancy after ART. Indeed the vast majority of studies
have concluded that AMH is not an independent prognostic marker
for pregnancy outcome (Nelson et al., 2007; La Marca et al., 2010),
suggesting that the basal serum AMH level is a marker of
quantitative rather than qualitative aspects of the ovarian reserve.
There are only sparse data on AMH in the follicular ﬂuid (FF).
However, it has been suggested that AMH in FF, but not in serum,
is positively associated with embryo implantation and clinical
pregnancy rate (Fanchin et al., 2007).
The aim of the present retrospective study was to evaluate the
associations between serum and FF AMH levels and ovarian response
(including endocrine variables), embryo quality as well as ongoing
pregnancy rates after stimulation with two different gonadotrophin
preparations, highly puriﬁed menotrophins (HP-hMG) and rFSH, in
GnRH agonist cycles for IVF. Also, this study compared the serum
AMH dynamics during COS between the two treatment groups.
Materials and Methods
Study population
This study is a retrospective analysis of data derived from a randomized,
active-controlled, assessor-blind, multicentre, multinational trial; the
details of which have been described previously (Nyboe Andersen et al.,
2006). The trial compared pregnancy rates in patients (n ¼ 731) undergo-
ing IVF after stimulation with HP-hMG (Menopur; Ferring Pharmaceuticals
A/S, Copenhagen, Denmark) or rFSH (follitropin alfa, Gonal-F; Merck
Serono, Geneva, Switzerland). Main inclusion criteria were patients with
major indications for IVF such as tubal factor infertility or unexplained in-
fertility including endometriosis stage I/II or partners with mild semen ab-
normalities not requiring ICSI, an age of at least 21 but not more than 37
years, a body mass index (BMI) of 18–29 kg/m
2, FSH within normal limits
(1–12 IU/l), regular menstrual cycles of 21–35 days which were pre-
sumed to be ovulatory and a willingness to accept transfer of one or
two embryos. The randomization of patients to treatment were stratiﬁed
by age (,35 and 35–37 years). Patients with polycystic ovary syndrome,
endometriosis stage III/IV or partners with severe male factors requiring
ICSI were excluded as poor responders; the study population consisted
of infertile women with favorable prognosis.
Study protocol
Patients underwent COS following down-regulation with a GnRH agonist
in a long protocol. Pituitary suppression with triptorelin acetate, 0.1 mg/day
subcutaneously (Decapeptyl; Ferring Pharmaceuticals A/S), was initiated
5–7 days before the estimated start of next menses and continued until
the end of gonadotrophin administration. Prior to start of ovarian stimula-
tion, the antral follicle count (AFC; follicles .2 mm) was recorded by
transvaginal ultrasound (TVU) of the ovaries by one or more operators
at the clinics and follicular development was monitored after 5 days of
treatment and thereafter at least every 2 days. Stimulation with
HP-hMG or rFSH was started at a dose of 225 IU/day for the ﬁrst 5
days and was followed by individual dose-adjustments according to the
patient’s follicular response as exclusively measured by TVU. The daily
dose could either be increased or decreased by 75 IU per adjustment
and not changed more frequently than every fourth day. Recombinant
hCG (choriongonadotrophin alfa, Ovitrelle; Merck Serono), 250 mg sub-
cutaneously, was used to induce ﬁnal follicular maturation when three
or more follicles of ≥17 mm in diameter were observed and was adminis-
tered 36+2 h before planned oocyte retrieval. Coasting was not allowed.
The target for the ovarian stimulation was set to be 7–15 oocytes at re-
trieval as 7 or more oocytes are considered to give reasonable chances
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hyperstimulation syndrome (OHSS) is low in patients with ≤15 oocytes
(Arce et al., 2005). Criteria for cycle cancellation at the day of hCG admin-
istration were either inability to reach the hCG criterion or .25 follicles
with a diameter of ≥10 mm.
A top-quality embryo (TQE) was deﬁned as four to ﬁve cells on Day 2,
seven or more cells on Day 3, equally
-sized blastomeres and ≤20% frag-
mentation on Day 3 and no multinucleation. The transfer of one or two
embryos was done on Day 3 after oocyte retrieval according to local prac-
tise within any country speciﬁc regulations. Vaginal progesterone gel of
90 mg/day 8% (Crinone; Merck Serono) for luteal support was given
from the day of embryo transfer until the conﬁrmation of clinical pregnancy
(5–6 weeks after embryo transfer) or negative serum hCG test (13–15
days after embryo transfer).
Collection and handling of serum
Blood samples for AMH analysis were drawn on Days 1 and 6 and on the
last day of stimulation as well as the day of oocyte retrieval. The sample on
Day 1 was taken before the start of gonadotrophin administration and the
samples on Day 6 and last stimulation day were collected at least 8 h after
the previous gonadotrophin dose. Blood samples were centrifuged for
10 min at 1800g. Serum was stored individually at 2188C or colder at
the clinic for a maximum of 2 weeks before transfer to 2708C and sub-
sequent analysis at a central laboratory. The sera were only thawed once.
Collection and handling of FF
AMH measurements in FF were performed in those patients who had
oocyte retrieval. Fluid was collected from one follicle of ≥17 mm from
which an oocyte was retrieved. Fluid was preferably collected from the
ﬁrst follicle aspirated and from follicles where ﬂushing had not been per-
formed. The ﬂuid was centrifuged for 10 min at 1000g and the supernatant
was stored under the same conditions as serum. Fluids that were found to
be contaminated by red blood cells or ﬂushing medium were not included
in the analysis.
Analytical methods for the variables
measured in serum and FF
Serum and FF AMH analysis was performed batch wise in a single labora-
tory (hormone laboratory at Universitair Ziekenhuis, Brussels) to minimize
variability. AMH was measured with the Immunotech Beckman Coulter
AMH ELISA kit (A11893). The intra-assay and inter-assay coefﬁcients of
variation were ,9.5%. Functional sensitivity of the assay was 2.5 pmol/l
(1 ng/ml ¼ 7.14 pmol/l).
Serum was analysed for other endocrine variables by a central labora-
tory using electrochemiluminescence immunoassays (FSH, LH, hCG),
chemiluminescent immunometric assays (estradiol, progesterone, SHBG)
and radioimmunoassays (androstenedione, total testosterone). The sensi-
tivity [and total imprecision (coefﬁcient of variation, CV)] of the validated
analytical methods were as follows: FSH ,0.1 IU/l (,6%), LH ,0.1 IU/l
(,6%), hCG ,0.1 IU/l (,8%), estradiol 55 pmol/l (10%), progesterone
0.6 nmol/l (,8%), SHBG 0.02 nmol/l (10%), androstenedione
0.08 nmol/l (10%) and total testosterone 0.17 nmol/l (5%).
FF was analysed for endocrine variables by a central laboratory using
electrochemiluminescence assays (FSH, LH, hCG, estradiol, progesterone,
SHBG), radioimmunoassays (androstenedione, total testosterone, cortisol,
cortisone) and ELISA (inhibin A, VEGF, IGF-1). The sensitivity (and total
imprecision, CV) were as follows: FSH ,0.1 IU/l (,5%), LH 0.1 IU/l
(,5%), hCG ,0.1 IU/l (,8%), estradiol 18 pmol/l (,5%), progesterone
0.095 nmol/l (,5%), SHBG 0.35 nmol/l (,5%), androstenedione
0.13 nmol/l (,12%), total testosterone 0.1 nmol/l (,8%), cortisol
20 nmol/l (,8%), cortisone 4 nmol/l (,10%), inhibin A 1.0 ng/l (9%),
VEGF ,9.0 ng/l (7%) and IGF-1 0.105 nmol/l (10%).
Statistical analysis
The study cohort comprised all patients with AMH measurements at the
start of the stimulation. The endocrine variables are reported using median
and inter-quartile range (IQR) due to non-symmetric distributions. Spear-
man’s rank correlation coefﬁcient was used to quantify the association
between pairs of variables. Due to the high number of observations, a
large proportion of the calculations lead to signiﬁcant correlations. To
avoid multiplicity, mainly highly signiﬁcant (P , 0.001) clinically relevant
(r . 0.30) correlations were considered of interest.
The relationships between serum AMH at the start of the stimulation
and baseline, stimulation and outcome characteristics were evaluated
using regression models. In all models, AMH was included as covariate
and treatment was included as a factor. ANCOVA models were utilized
for continuous variables, while categorical outcomes were modelled
using logistic regression for binary outcomes and proportional odds
models for ordinal outcomes. Receiver operating characteristic (ROC)
curves were used to evaluate the ability of AMH to discriminate
between relevant outcomes of stimulation. ROC curves were based on
simple logistic regression models using AMH as a covariate.
Results
Serum AMH at the start of the stimulation
Amongst the 731 patients who initiated COS, 623 patients had serum
AMH measurements on stimulation day 1: 314 patients treated with
HP-hMG and 309 patients treated with rFSH. There were no apparent
differences between the two treatment groups with respect to demo-
graphics, baseline characteristics and serum hormone concentrations
at the start of the stimulation (Table I).
Inthetotalcohort,themedian(IQR)concentrationofserumAMHat
the start ofthe stimulationaftertwoweeksofpituitary down-regulation
with GnRH agonist was 26.0 (16.8, 37.4) pmol/l (Table I). The two
treatment groups were similar with respect to median basal AMH in
the various age categories. There was a signiﬁcant (P , 0.001) negative
correlationbetweenserumAMHatthestartofthe stimulationand age,
eventhoughthecorrelationcoefﬁcientwasrelativelysmall(r ¼ 20.25).
The serum concentration of AMH was positively correlated with
AFC (r ¼ 0.35, P , 0.001), while the correlation between age and
AFC was weak (r ¼ 20.08, P ¼ 0.046). Also, only weak correlations
(r ≤ 0.15) were observed at the start of the stimulation between
serumAMHandserumconcentrationsofFSH,LH,estradiol,progester-
one, androstenedione, SHBG, total testosterone and free androgen
index.
Serum AMH during stimulation
The serum AMH concentration decreased gradually during COS and
showedsimilardynamicchangesinbothtreatmentgroups,althoughasig-
niﬁcantly (P , 0.001) larger reduction was noted during stimulation with
rFSHthanwithHP-hMG.IntherFSHgroup,themedianAMH(IQR)con-
centrationwasdecreasedby30%to18.6(12.8,27.5) pmol/lonDay6of
stimulationandby55%to11.9(8.1,16.9) pmol/lonthelastdayofstimu-
lation, while the median AMH concentration was decreased by 16% to
21.4 (14.9, 32.7) pmol/l on Day 6 and 46% to 13.7 (10.3, 19.6) pmol/l
on the last day of stimulation in the HP-hMG group. The serum
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correlated with the serum concentration on Day 6 and on the last day of
stimulationinbothtreatmentgroups(HP-hMGgroup:r ¼ 0.91and0.82,
respectively;rFSHgroup:r ¼ 0.93and0.84,respectively).Themagnitude
ofthedecreasesinserumAMHfrombaselinetostimulationday6aswell
as during the whole stimulation period was correlated (P , 0.001) with
the number of follicles ≥10 mm on Day 6 and on the last stimulation
day (HP-hMG group: r ¼ 0.33 and 0.51, respectively; rFSH group: r ¼
0.38 and 0.57, respectively).
Serum AMH association with endocrine
values
Serum concentrations of estradiol and androstenedione on Day 6 of
stimulation were found to be signiﬁcantly (P , 0.001) positively
correlated with the serum AMH concentrations at the start of stimula-
tion (HP-hMG group: r ¼ 0.38 and 0.31, respectively; rFSH group: r ¼
0.58and0.34,respectively).Also,signiﬁcant (P , 0.001)positivecorre-
lationswereobservedbetweenserumAMH concentrationsat thestart
ofstimulationandconcentrations,onthelaststimulationdayandonthe
dayofoocyteretrievalrespectively,ofserumestradiol(HP-hMGgroup:
r ¼ 0.45and0.49,respectively;rFSHgroup:r ¼ 0.55and0.53,respect-
ively), androstenedione (HP-hMG group: r ¼ 0.50 and 0.52,
respectively;rFSHgroup:r ¼ 0.49and0.49,respectively),andtotaltes-
tosterone(HP-hMGgroup:r ¼ 0.40and0.44,respectively;rFSHgroup:
r ¼ 0.36 and 0.39, respectively). The serum progesterone concentra-
tion at oocyte retrieval was also signiﬁcantly (P , 0.001) correlated
with serum AMH measured at the start of the stimulation (HP-hMG
group: r ¼ 0.39; rFSH group: r ¼ 0.50). Correlations between serum
AMH at the start of the stimulation and all other endocrine variables
in serum measured on Day 6 or at the end of the stimulation were
,0.30. Similar relationships between AMH and endocrine variables
were observed when using AMH concentrations on Day 6 or at the
end of stimulation instead of AMH at the start of the stimulation.
.............................................................................................................................................................................................
Table I Patient demographics, baseline characteristics and serum endocrine concentrations at the start of the
stimulation.
Variable All
a (n 5 623) HP-hMG
a (n 5 314) rFSH
a (n 5 309)
Baseline
Age (years), mean (SD) 30.8 (3.3) 30.8 (3.2) 30.8 (3.4)
Weight (kg), mean (SD) 62.1 (8.4) 62.8 (8.5) 61.3 (8.3)
BMI (kg/m
2), mean (SD) 22.3 (2.6) 22.5 (2.7) 22.1 (2.6)
Duration of infertility (years), mean (SD) 3.9 (2.2) 3.9 (2.3) 3.9 (2.2)
Primary cause of infertility
Tubal infertility, n (%) 213 (34%) 116 (37%) 97 (31%)
Mild male factor, n (%) 59 (9%) 29 (9%) 30 (10%)
Other (incl. endometriosis I/II), n (%) 65 (10%) 31 (10%) 34 (11%)
Unexplained infertility, n (%) 286 (46%) 138 (44%) 148 (48%)
Duration of GnRH agonist before the start of stimulation (days) 15.1 (4.0) 15.1 (4.1) 15.1 (3.9)
Day 1 of stimulation
Mean ovarian volume (ml) 4.3 (3.0, 5.9) 4.4 (3.1, 5.9) 4.3 (2.9, 5.9)
AFC 10 (7, 14) 10 (7, 14) 10 (7, 14)
21–29 years 11 (7, 16); n ¼ 209 11 (8, 16); n ¼ 105 10 (7, 16); n ¼ 104
30–34 years 10 (7, 14); n ¼ 316 9 (7, 14); n ¼ 165 10 (7, 14); n ¼ 151
35–37 years 10 (7, 14); n ¼ 94 10 (7, 14); n ¼ 42 9 (7, 14); n ¼ 52
FSH (IU/l) 3.7 (2.9, 4.7) 3.7 (2.9, 4.7) 3.8 (3.0, 4.7)
LH (IU/l) 1.9 (1.4, 2.7) 1.8 (1.3, 2.7) 2.0 (1.5, 2.6)
Progesterone (nmol/l) 1.2 (0.9, 1.5) 1.2 (0.9, 1.5) 1.1 (0.9, 1.5)
Androstenedione (nmol/l) 4.1 (3.1, 5.4) 4.3 (3.1, 5.5) 3.9 (3.0, 5.1)
Total testosterone (nmol/l) 0.6 (0.5, 0.9) 0.6 (0.5, 0.9) 0.6 (0.4, 0.8)
SHBG (nmol/l) 55 (42, 71) 56 (40, 72) 55 (42, 69)
Free androgen index 1.1 (0.7, 1.7) 1.2 (0.8, 1.8) 1.1 (0.7, 1.7)
AMH (pmol/l) 26.0 (16.8, 37.4) 25.5 (17.2, 36.1) 26.6 (16.4, 37.9)
21–29 years 30.7 (20.1, 44.8); n ¼ 210 30.7 (20.7, 46.6); n ¼ 106 30.7 (18.7, 41.4); n ¼ 104
30–34 years 25.1 (16.3, 37.2); n ¼ 317 24.3 (16.3, 34.0); n ¼ 165 26.5 (16.4, 38.9); n ¼ 152
35–37 years 19.0 (11.9, 27.9); n ¼ 96 19.7 (13.3, 27.9); n ¼ 43 18.4 (11.5, 27.9); n ¼ 53
Values are median (IQR) unless otherwise indicated.
aPatients with AMH measurement at the start of stimulation.
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Oocyteretrievalwasperformedfor95%ofthepatientswithAMHmeas-
urement at stimulation Day 1: 299 and 294 patients in the HP-hMG and
rFSH groups, respectively. The median (IQR) number of oocytes
retrieved was signiﬁcantly (P , 0.001) higher in the rFSH group com-
pared with the HP-hMG group: 11 (8, 16) versus 9 (6, 13). The serum
concentrations of AMH on stimulation days 1, 6 and last day were all sig-
niﬁcantly (P , 0.001) positively correlated with the number of oocytes
retrieved. In both treatment groups, the correlations were stronger for
basal AMH (HP-hMG: r ¼ 0.48; rFSH: r ¼ 0.62) than for AMH on Day
6( H P - h M G :r ¼ 0.42; rFSH: r ¼ 0.58) or AMH on the last day
(HP-hMG: r ¼ 0.35; rFSH:
r ¼ 0.48). Compared with AMH, AFC was less strongly correlated
with the number of oocytes retrieved (HP-hMG group: r ¼ 0.19, P ¼
0.001; rFSH group: r ¼ 0.36, P , 0.001). ROC analyses were
performed to assess the predictive value of serum AMH on stimulation
day 1 for estimation of oocyte retrievals below and above the target, re-
spectively. The predictive performance of the two models was high in
both treatment groups (below the target: 0.764 and 0.908 for
HP-hMG and rFSH, respectively; above the target: 0.781 and 0.807 for
HP-hMG and rFSH, respectively; Fig. 1). The corresponding ROC
values for AFC were signiﬁcantly (P , 0.05) lower (below the target:
0.618 and 0.699 for HP-hMG and rFSH, respectively; above the target:
0.630 and 0.675 for HP-hMG and rFSH, respectively) than for AMH.
Baseline, stimulation and outcome
characteristics according to AMH percentiles
The whole patient population was stratiﬁed according to the 25, 50
and 75th percentiles of serum AMH concentration at the start of
stimulation. Baseline characteristics, stimulation characteristics,
embryo quality and pregnancy rates per AMH quartile for all patients
and for each treatment group are presented in Table II. There were
signiﬁcant (P , 0.001) differences between quartiles for all outcome
variables except for the number of TQEs, when accounting for the
number of oocytes retrieved, and the ongoing pregnancy rate. In
both the HP-hMG and rFSH treatment groups, patients with lower
AMH concentrations required higher total gonadotrophin doses and
more treatment days to reach the hCG criteria than patients with
higher AMH concentrations. Despite this, fewer oocytes were
retrieved and the proportion below the stimulation target was
higher in patients with lower AMH concentrations compared with
patients with higher AMH concentrations. In contrast, cycle cancella-
tions due to excessive response and cycles with ovarian response
above the target and moderate/severe early OHSS were most
frequent in patients in the highest AMH quartile.
Therefore, across the AMH quartiles, there were signiﬁcant differ-
ences between the treatment groups in terms of dose adjustments on
Day 6 (P ¼ 0.034), mean gonadotrophin dose (P ¼ 0.047) and total
gonadotrophin dose (P ¼ 0.025), duration of stimulation (P ¼ 0.042)
and ovarian response with respect to number of oocytes retrieved
below/above the stimulation target (P , 0.001).
Serum AMH association with mid-follicular
gonadotrophin-dose adjustments
Table III presents baseline characteristics, stimulation characteristics,
embryo quality and pregnancy rates in relation to the gonadotrophin-
dose adjustments on stimulation Day 6. The patients who increased
the daily dose from 225 to 300 IU had a lower median serum AMH
concentration prior to stimulation, received a higher total
Figure 1 ROC curve analysis showing the predictive value of serum AMH at the start of the stimulation for the estimation of number of oocytes at
retrieval below (,7) (A) and above (.15) the target (B) after COS in patients treated with HP-hMG or rFSH in the long GnRH agonist protocol. The
diagonal line is the reference line of no discrimination (AUC ¼ 0.5). Cut-off values for response below the target were 21.2 pmol/l for HP-hMG (sens.
66.7%, spec. 75.2%) and 16.4 pmol/l for rFSH (sens. 81.0%, spec. 88.3%). The cut-off values for response above the target were 29.8 pmol/l for
HP-hMG (sens. 73.3%, spec. 67.0%) and 29.5 pmol/l for rFSH (sens. 82.5%, spec. 70.4%).
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Table II Baseline, stimulation and outcome variables grouped by AMH quartiles at the start of the stimulation.
Variable AMH quartiles
<P25
a P25–P50
b >P50–P75
c >P75
d P-value
(AMH)
P-value
(treatment)
All
(n 5 155)
HP-hMG
(n 5 73)
rFSH
(n 5 82)
All
(n 5 156)
HP-hMG
(n 5 86)
rFSH
(n 5 70)
All
(n 5 157)
HP-hMG
(n 5 79)
rFSH
(n 5 78)
All
(n 5 155)
HP-hMG
(n 5 76)
rFSH
(n 5 79)
Serum AMH at the start of stimulation (pmol/l)
e
Mean
IQR
12.4
(10.1, 15.2)
13.5
(10.6, 15.4)
12.1
(9.3, 14.8)
21.3
(18.5, 23.6)
21.2
(18.8, 23.3)
21.6
(18.3, 23.7)
31.7
(28.8, 34.3)
30.6
(28.7, 33.6)
33.2
(28.9, 35.1)
50.3
(41.1, 60.6)
50.3
(42.3, 61.0)
50.3
(40.9, 60.2)
Age (years)
f 32.0 (3.4) 32.2 (3.3) 31.8 (3.5) 30.8 (3.3) 30.6 (3.3) 31.1 (3.2) 30.5 (3.2) 30.6 (3.0) 30.3 (3.5) 29.9 (3.0) 29.9 (2.9) 30.0 (3.1) ,0.001
g 0.952
g
AFC
e 7 (5, 10) 7 (5, 11) 7 (4, 9) 10 (7, 14) 10 (7, 13) 12 (7, 14) 11 (8, 16) 11 (8, 16) 11 (8, 16) 11 (8, 18) 12 (8, 20) 11 (8, 16) ,0.001
g 0.868
g
FSH at the start of stimulation
(IU/l)
e
4.0 (3.0, 5.1) 3.6 (3.0, 5.0) 4.2 (3.0, 5.2) 3.8 (3.0, 4.6) 4.0 (3.2, 4.8) 3.4 (3.0, 4.4) 3.7 (3.1, 4.6) 3.7 (3.1, 4.4) 3.7 (3.0, 4.7) 3.4 (2.7, 4.4) 3.2 (2.6, 4.4) 3.6 (2.8, 4.4) 0.084
g 0.382
g
Dose adjustment on stimulation
day 6
,0.001
h 0.034
h
Decrease, n (%) 2 (1) 1 (1) 1 (1) 7 (4) 4 (5) 3 (4) 10 (6) 6 (8) 4 (5) 37 (24) 13 (17) 24 (30)
No change, n (%) 75 (48) 34 (47) 41 (50) 104 (67) 56 (65) 48 (69) 123 (78) 55 (70) 68 (87) 104 (67) 55 (72) 49 (62)
Increase, n (%) 78 (50) 38 (52) 40 (49) 45 (29) 26 (30) 19 (27) 24 (15) 18 (23) 6 (8) 14 (9) 8 (11) 6 (8)
Gonadotrophin dose on
stimulation day 6 (IU)
f
262 (40) 263 (40) 261 (40) 243 (39) 244 (40) 242 (39) 232 (34) 236 (40) 227 (27) 214 (42) 220 (39) 208 (43) ,0.001
g 0.047
g
Number of treatment days
f 11.2 (2.4) 11.5 (2.6) 10.9 (2.1) 10.2 (1.5) 10.1 (1.6) 10.3 (1.5) 10.2 (1.4) 10.5 (1.5) 9.9 (1.2) 9.8 (1.5) 10.0 (1.5) 9.7 (1.5) ,0.001
g 0.042
g
Total gonadotrophin dose (IU)
f 2874 (942) 2975 (1022) 2783 (860) 2452 (578) 2432 (620) 2476 (526) 2341 (467) 2452 (554) 2229 (325) 2130 (426) 2199 (438) 2063 (406) ,0.001
g 0.025
g
Cycle cancelled
Poor response, n (%) 13 (8) 7 (10) 6 (7) 2 (1) 2 (2) 0 (0) 1 (1) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) ,0.001
h 0.127
h
High response, n (%) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 1 (1) 1 (1) 0 (0) 1 (1) 7 (5) 3 (4) 4 (5) ,0.001
h 0.278
h
Early OHSS (moderate/severe),
n (%)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 1 (1) 0 (0) 7 (5) 3 (4) 4 (5) ,0.001
h 0.982
h
Oocytes retrieved (OR)
e
Mean
IQR
6
(5, 9)
6
(4, 9)
6
(5, 9)
10
(7, 12)
8
(7, 11)
11
(8, 13)
12
(8, 16)
11
(7, 15)
13
(11, 18)
14
(10, 18)
12
(9, 16)
15
(11, 20)
,0.001
g ,0.001
g
According to target ,0.001
h ,0.001
h
Below target (,7 oocytes),
n (%)
92 (60) 45 (63) 47 (57) 32 (21) 22 (26) 10 (14) 18 (12) 17 (22) 1 (1) 6 (4) 6 (8) 0 (0)
Within target (7–15
oocytes), n (%)
60 (39) 26 (36) 34 (41) 109 (70) 57 (66) 52 (74) 93 (60) 48 (61) 45 (58) 83 (55) 46 (61) 37 (48)
Above target (.15 oocytes),
n (%)
2 (1) 1 (1) 1 (1) 15 (10) 7 (8) 8 (11) 45 (29) 14 (18) 31 (40) 63 (41) 23 (31) 40 (52)
TQEs
f 0.6 (0.9) 0.5 (0.9) 0.7 (1.0) 0.9 (1.3) 1.0 (1.1) 0.9 (1.5) 1.1 (1.6) 1.0 (1.4) 1.2 (1.7) 1.4 (2.1) 1.5 (2.3) 1.3 (2.0) ,0.001
g 0.830
g
TQE/OR (%)
f 8.6 (14.9) 8.4 (16.5) 8.8 (13.5) 9.5 (13.2) 10.9 (13.5) 7.8 (12.7) 9.3 (11.9) 9.9 (12.5) 8.6 (11.3) 10.2 (15.0) 11.9 (17.3) 8.4 (12.1) 0.290
g 0.094
g
Ongoing pregnancy, n (%) 29 (19) 9 (12) 20 (24) 52 (33) 26 (30) 26 (37) 39 (25) 26 (33) 13 (17) 41 (26) 25 (33) 16 (20) 0.915
h 0.374
h
a,16.8 pmol/l.
b16.8–26.0 pmol/l.
c26.1–37.4 pmol/l.
d.37.4 pmol/l.
eMedian (IQR).
fMean (SD).
gANCOVA.
hLogistic regression.
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Table III Baseline, stimulation and outcome variables in relation to gonadotrophin-dose adjustments on stimulation day 6.
Variable Dose adjustment
Increase No change Decrease
All
(n 5 161)
HP-hMG
(n 5 90)
rFSH
(n 5 71)
All
(n 5 406)
HP-hMG
(n 5 200)
rFSH
(n 5 206)
All
(n 5 56)
HP-hMG
(n 5 24)
rFSH
(n 5 32)
Serum AMH at the start of
stimulation (pmol/l)
a
16.9 (11.8, 24.4) 18.7 (13.8, 28.7) 14.8 (10.3, 21.6) 27.9 (18.9, 38.0) 27.6 (19.6, 38.6) 28.2 (18.5, 37.2) 47.9 (34.2, 57.7) 41.3 (27.5, 52.1) 49.4 (36.6, 60.1)
Age (years)
b 31.9 (3.3) 31.9 (3.1) 31.8 (3.5) 30.6 (3.2) 30.4 (3.2) 30.7 (3.3) 29.4 (3.1) 30.2 (3.3) 28.9 (2.9)
AFC
a 9 (6, 12) 9 (7, 12) 9 (6, 11) 10 (7, 14) 10 (7, 15) 10 (7, 14) 15 (10, 21) 13 (10, 19) 16 (11, 24)
FSH at the start of stimulation
(IU/l)
a
3.5 (2.8, 4.6) 3.6 (2.8, 4.6) 3.4 (2.8, 4.6) 3.8 (3.0, 4.9) 3.8 (3.0, 4.8) 3.9 (3.0, 5.0) 3.5 (2.9, 4.4) 3.6 (2.6, 4.6) 3.5 (3.1, 4.3)
Gonadotrophin dose on
stimulation day 6 (IU)
300 300 300 225 225 225 150 150 150
Number of treatment days
b 11.5 (2.0) 11.7 (2.1) 11.4 (2.0) 10.1 (1.5) 10.1 (1.6) 10.0 (1.3) 9.0 (1.6) 9.3 (1.6) 8.8 (1.5)
Total gonadotrophin dose (IU)
b 3164 (780) 3212 (808) 3102 (746) 2267 (415) 2282 (459) 2252 (368) 1714 (227) 1744 (238) 1692 (220)
Cycle cancelled
Poor response, n (%) 10 (6) 8 (9) 2 (3) 6 (1) 2 (1) 4 (2) 0 (0) 0 (0) 0 (0)
High response, n (%) 0 (0) 0 (0) 0 (0) 5 (1) 2 (1) 3 (1) 4 (7) 1 (4) 3 (9)
Early OHSS (moderate/severe),
n (%)
0 (0) 0 (0) 0 (0) 5 (1) 3 (2) 2 (1) 3 (5) 1 (4) 2 (6)
Oocytes retrieved (OR)
a 8 (5, 11) 8 (5, 10) 8 (6, 12) 11 (7, 15) 10 (7, 13) 12 (8, 16) 15 (11, 20) 12 (10, 15) 17 (12, 20)
Below target, n (%) 63 (39) 38 (42) 25 (35) 82 (20) 50 (25) 32 (16) 3 (5) 2 (8) 1 (3)
Within target, n (%) 87 (54) 45 (50) 42 (59) 232 (58) 116 (59) 116 (57) 26 (46) 16 (67) 10 (31)
Above target, n (%) 11 (7) 7 (8) 4 (6) 87 (22) 32 (16) 55 (27) 27 (48) 6 (25) 21 (66)
TQEs
b 0.6 (0.9) 0.6 (0.8) 0.6 (1.0) 1.1 (1.7) 1.2 (1.8) 1.1 (1.6) 1.3 (1.8) 0.8 (1.2) 1.6 (2.1)
TQE/OR (%)
b 7.6 (12.5) 7.5 (11.6) 7.6 (13.5) 10.2 (14.4) 12.0 (16.4) 8.5 (11.9) 8.3 (11.1) 6.3 (8.8) 9.9 (12.6)
Ongoing pregnancy, n (%) 34 (21) 20 (22) 14 (20) 109 (27) 58 (29) 51 (25) 18 (32) 8 (33) 10 (31)
aMedian (IQR).
bMean (SD).
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5gonadotrophin dose and had slightly longer stimulation periods com-
pared with the other patients. Despite this, cycle cancellation rate
due to poor response or response below the target appeared more
frequently in the group of patients with dose increases compared
with the patients who continued on the starting dose. The patients
who decreased the dose to 150 IU at stimulation day 6 appeared to
have a higher median serum AMH concentration prior to stimulation
and they consumed less gonadotrophin, had slightly shorter stimula-
tion periods and a higher incidence of cancellations due to excessive
response and of moderate/severe early OHSS compared with the
patients with no dose adjustment.
Figure 2 shows the ROC curve analyses performed to assess the
predictive value of serum AMH at the start of the stimulation for
the need for a gonadotrophin dose increase or dose decrease on
stimulation day 6, respectively, for each treatment group and all
patients. The predictive performance of the two models was high
in both treatment groups (dose increase: 0.713 and 0.781 for
HP-hMG and rFSH, respectively; dose decrease: 0.736 and 0.838
for HP-hMG and rFSH, respectively).
FF AMH at oocyte retrieval
Amongst the 731 patients who initiated COS, 582 patients had AMH
measurements in ﬂuid from one large follicle (≥17 mm) at oocyte
retrieval: 290 patients treated with HP-hMG and 292 patients
treated with rFSH. The median (IQR) concentration of FF AMH at
oocyte retrieval was signiﬁcantly higher in the HP-hMG group com-
pared with the rFSH group [19.1 (14.2, 27.6) pmol/l versus 17.5
(12.0, 24.8) pmol/l, P ¼ 0.007]. The AMH concentration in FF
declined signiﬁcantly with increased female age in both treatment
groups. For the age categories 21–29, 30–34 and 35–37 years, the
median (IQR) concentrations (pmol/l) in the HP-hMG group were
21.5 (15.0, 33.0; n ¼ 100), 18.2 (14.9, 27.2; n ¼ 151) and 14.8
(10.3, 23.0; n ¼ 39), respectively and the corresponding values in
the rFSH group were 19.6 (13.1, 26.9; n ¼ 98), 16.5 (11.9, 24.3;
n ¼ 147) and 15.2 (9.8, 20.5; n ¼ 47). As with for serum AMH, the
coefﬁcients for correlation between FF AMH and age were rather
small in both treatment groups (HP-hMG group: r ¼ 20.17,
P ¼ 0.004; rFSH group: r ¼ 20.20, P , 0.001).
The AMH concentration in FF was signiﬁcantly (P , 0.001) corre-
lated with the AMH concentration in serum at the start of the stimu-
lation, on Day 6 and on the last day of stimulation (HP-hMG group:
r ¼ 0.55, 0.59, and 0.64, respectively; rFSH group: 0.61, 0.59 and
0.63, respectively). All correlations between FF AMH and other FF
endocrine variables (LH, hCG, inhibin A, estradiol, progesterone,
androstenedione, total testosterone, SHBG, insulin, IGF-1, IGFBP-1,
VEGF, cortisol and cortisone) were weak (r , 0.22) in both treatment
groups, except for a negative correlation with FSH (HP-hMG group:
r ¼ 20.33, P , 0.001; rFSH group: r ¼ 20.29, P , 0.001) and a posi-
tive correlation with inhibin B (HP-hMG group: r ¼ 0.37, P , 0.001;
rFSH group: r ¼ 0.30, P , 0.001). The correlation between FF AMH
and embryo quality was not estimated, since the AMH value of a
speciﬁc follicle could not be linked to an individual oocyte/embryo.
Serum AMH association with outcome
As shown in Table II, there was no signiﬁcant linear association
between serum AMH concentrations at the start of stimulation and
ongoing pregnancy. ROC analyses were performed to assess the
predictive value of serum AMH on stimulation day 1 for prediction
of ongoing pregnancy. The predictive performance of serum
AMH for ongoing pregnancy was low in both treatment groups
Figure 2 ROC curve analysis showing the predictive value of serum AMH at the start of the stimulation for the need for a gonadotrophin-dose
increase (A) or decrease (B) on stimulation day 6 in patients treated with HP-hMG or rFSH in the long GnRH agonist protocol. All patients had
received starting doses of 225 IU/day for the ﬁrst 5 days. The diagonal line is the reference line of no discrimination (AUC ¼ 0.5). Cut-off values
for increased dose were 23.0 pmol/l for HP-hMG (sens. 67.8%, spec. 67.1%) and 21.4 pmol/l for rFSH (sens. 74.6%, spec. 73.6%). The cut-off
values for decreased dose were 32.4 pmol/l for HP-hMG (sens. 70.8%, spec. 72.6%) and 37.4 pmol/l for rFSH (sens. 75.0%, spec. 80.7%).
1836 Anckaert et al.(AUC ¼ 0.609 and 0.546 in the HP-hMG and rFSH groups,
respectively), as shown in Fig. 3.
Discussion
This study conﬁrms that the serum AMH concentration during COS
reﬂects the steady decline in the AMH-secreting follicle pool
(Fanchin et al., 2003b, La Marca et al., 2004, Lee et al., 2010), as a
signiﬁcant gradual decrease of serum AMH was noticed in both the
HP-hMG and rFSH treatment groups. The lower decline in serum
AMH and the higher AMH concentration in FF at oocyte retrieval in
the HP-hMG group compared with the rFSH group can be readily
explained by the less pronounced follicle growth observed during
the initial stimulation and the lower number of follicles/oocytes
retrieved after stimulation with HP-hMG (Nyboe Andersen et al.,
2006; Smitz et al., 2007).
The positive correlations between the serum concentrations of
AMH and estradiol and androgens, measured during gonadotrophin
stimulation, and with progesterone measured at oocyte retrieval
may suggest that the AMH concentration after pituitary down-
regulation reﬂects the capacity of a follicle pool to become steroido-
genically active after stimulation and the luteinization potential of the
selected cohort. The stronger correlation between serum AMH at
the start of the stimulation and the serum estradiol concentration
on stimulation day 6 in the rFSH group compared with the HP-hMG
group may reﬂect the early estrogenization of a larger fraction of fol-
licles recruited in the rFSH group (Nyboe Andersen et al., 2006; Smitz
et al., 2007). Also, the apparent difference between the treatment
groups regarding the correlation between serum AMH and the
periovulatory progesterone concentration could imply a difference in
the number of recruitable follicles achieving the pre-ovulatory stage
as serum progesterone concentration at the end of the follicular
phase has been shown to be related to FSH exposure and the
number of growing follicles (Ubaldi et al., 1996; Fleming and Jenkins,
2010). In both treatments, there was a positive correlation between
AMH in FF and inhibin B in FF supporting the view that the inhibin
B concentration in FF reﬂects the quantity of immature granulosa
cells in the small follicle pool (Groome et al., 1996; Welt et al., 1997).
The patients included in the present study were relatively young, in
the narrow range between 21 and 37 years of age, and the observed
inverse correlation between age and the serum concentration of AMH
was weaker than previously described (van Rooij et al., 2005, Tremel-
len et al., 2005; Seifer et al., 2011; Nelson et al., 2011). Previous
studies have shown that basal AMH and AFC assessed during the
early follicular phase are highly correlated (van Rooij et al., 2002; de
Vet et al., 2002; Fanchin et al., 2003a; Eldar-Geva et al., 2005), and
both factors are considered to have a similar clinical value for the pre-
diction of poor or excessive ovarian responses (Broer et al., 2009,
2010, 2011; La Marca et al., 2010). The present analysis veriﬁed the
strong positive relationship between the number of oocytes retrieved
and the serum AMH concentration prior to, during and at the end of
the stimulation in both treatment groups. The ﬁnding that AMH was
more strongly correlated with the number of oocytes retrieved than
was AFC may be explained by the fact that the AFC data in the
present study were derived from a large multicentre trial, while the
studies included in the meta-analyses by Broer et al. (2009, 2011)
were single-centre studies with potential less variation in the
operator-dependent AFC assessments.
In line with the vast majority of published studies evaluating the
value of AMH as a predictive marker in ART treatment (reviewed
by Broer et al., 2010; La Marca et al., 2010), this study demonstrated
that serum AMH is a predictive factor of oocyte quantity rather than
quality, irrespective of the gonadotrophin preparation used. Hence,
the ROC curve analyses indicated that the AMH concentration at
the start of the stimulation was a good predictor of poor as well as
excessive ovarian response in both treatment groups, while the
number of TQEs (when accounting for the number of oocytes
retrieved) and ongoing pregnancy rates were not different between
patients with high and low basal AMH concentrations.
It has been suggested previously that the FF AMH concentration at
oocyte retrieval, but not the serum AMH concentration, is positively
associated with embryo implantation and ongoing pregnancy rates
(Fanchin et al., 2007). However, the ﬁndings of the present study indi-
cated a strong correlation between the FF AMH concentration and the
serum AMH concentration on the last stimulation day which suggests
that the FF AMH level reﬂects the circulating AMH level, i.e. the whole
cohort of AMH-secreting antral follicles, and not the speciﬁc AMH
production of the recruited large follicle in which AMH expression is
considered to be undetectable (Weenen et al., 2004). This implies
that embryo quality may not be directly related to the FF AMH
level at oocyte retrieval. The lack of a signiﬁcant association
between serum AMH and pregnancy rate in the present study is in
accordance with observations in several earlier studies (van Rooij
et al., 2002; Pen ˜arrubia et al., 2005; Fic ¸icioglu et al., 2006; Smeenk
et al., 2007). So far, the attempts to identify cut-off levels for serum
AMH that are able to distinguish between pregnancy and non-
Figure 3 ROC curve analysis showing the predictive value of serum
AMH at the start of the stimulation for ongoing pregnancy in patients
treated with HP-hMG or rFSH in the long agonist protocol. The diag-
onal line is the reference line of no discrimination (AUC ¼ 0.5).
Clinical value of AMH in the long GnRH agonist protocol 1837pregnancy have not been successful as reviewed by Broer et al. (2010).
Only a few studies that were either limited by small numbers of
patients (Eldar-Geva et al., 2005; Elgindy et al., 2008) or a retrospect-
ive observational design (Lekamge et al., 2007) have suggested that
AMH can predict pregnancy outcome during IVF treatment.
However, their ﬁndings may be explained, at least in part, by increased
oocyte availability in patients with high AMH compared with patients
with low AMH.
In the current study, the clinical consequences of a ﬁxed starting
dose for all patients, irrespective of the different serum AMH concen-
trations at the start of the stimulation, were readily observable as dose
adjustments on stimulation day 6 were applied in approximately
one-third of the study population. Since the ROC curve analysis
showed that basal AMH was predictive of the need for a dose increase
or decrease in both treatment groups, it may be hypothesized that if
starting doses of gonadotrophins were set according to basal AMH
concentrations, there may have been more patients within target of
stimulation and less cancellations for poor or excessive response. A
prospective study should explore whether starting gonadotrophin
doses based on basal serum AMH values will optimize the ovarian
response, reduce cycle cancellation rates and reduce the risks
associated with excessive response.
In conclusion, the present study provides additional data to support
the clinical value of AMH in COS cycles following the long GnRH
agonist protocol. The study revealed a strong positive relationship
between serum AMH and ovarian response, to HP-hMG as well as
to rFSH, in terms of oocytes retrieved and the accompanying
endocrine response. AMH is a good predictor of the need for
gonadotrophin-dose adjustment on stimulation day 6 for patients
with a ﬁxed starting dose, but it does not predict embryo quality or
ongoing pregnancy rates. AMH may guide the selection of patient-
tailored gonadotrophin starting doses for a more optimal ovarian
response, and, more importantly, for reducing the clinical risks
associated with excessive response.
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